TECHNICAL PROGRAM - American Chemical Society Publications

MEDI TECHNICAL PROGRAM
54. Novel tumor-targeting anticancer drug
conjugate bearing a taxoid and a topotecan.
E. S. Zuniga,I.Ojima
55. Synthesis and biological evaluation of
novel carbocycle-containing combretastatin
A-4 analogs. R. Fürst,
C. Nowikow, A. Berenyi, G. F. Ecker,
W. Schmid, I. Zupko, U. Rinner
56. Design of potent guanase inhibitors
based on azepinomycin skeleton.
S. Chakraborty, R. Hosmane
57. Blocking the nuclear translocation of signal
transducer and activator of transcription
3 (STAT3) protein via membrane anchorage.
M. Avadisian, S. Fletcher,
B. Liu, W. Xu, P. Yue, A. D. Schimmer,
J. Turkson, C. Gradinaru, P. T. Gunning*
58. Development of PET and SPECT radiotracers
for the imaging of cancers overexpressing
the ErbB family of growth factor
receptors. E. B. Corcoran, H. T. Pham,
R. N. Hanson
59. Development of a second-generation antiandrogen
for treatment of castration-resistant
prostate cancer (CRPC). D. Yoo,
S. Ouk, C. Chen, C. Tran, J. Wongvipat,
C. L. Sawyers, M. E. Jung
60. Targeting the interaction of mixed lineage
leukemia 1 (MLL1) and wd repeat
domain 5 (WDR5) for new anticancer drug
design. H. Karatas, E. Townsend,
D. Bernard, Y. Dou, S. Wang
61. Rational design and evaluation of small
molecule DNA ligase inhibitors as potential
cancer chemotherapeutics.
G. E. Greco,X.Chen,L.A.Tobin,
R. A. Lapidus, M. Sadowska, A. J. Yang,
N. N. Nemieboka, A. D. MacKerell,
S. Zhong, F. V. Rassool, A. E. Tomkinson
62. Design, synthesis and evaluation of
dibenzo[c,h][1,6]naphthyridines as Top1
inhibitors and potential anticancer
agents. E. Kiselev, T. Dexhemier,
Y. Pommier, M. Cushman
63. Design and synthesis of ezrin inhibitors
for metastatic osteosarcoma.
G. W. Kosturko, G. Bulut, V. Rodriguez,
E. Glasgow, S. Hong, C. Khanna,
M. Brown, M. Paige, A. Üren
64. Small molecule prostate specific membrane
antigen inhibitors with Re/Tc for
the diagnosis and staging of prostate
cancer. G. Lu, K. P. Maresca,
S. M. Hillier, J. C. Marquis,
C. N. Zimmerman, W. C. Eckelman,
J. L. Joyal, J. W. Babich
65. Structure-based design, synthesis, and
evaluation of a new class of potent Bcl-2/
Bcl-X L inhibitors. H. Zhou, J. Chen,
A. Aguilar, X. Cong, L. Liu, L. Bai,
D. McEachern, C. Yang, H. Yi,
J. Meagher, J. A. Stuckey, X. Li, D. Sun,
S. Wang
66. Novel VEGFR2 inhibitors: Pyridylmethylthio
derivatives with intramolecular nonbonded
S-O interaction. H. Tajima,
T. Honda, K. Kawashima, Y. Sasabuchi,
M. Yamamoto, M. Ban, K. Okamoto,
K. Inoue, T. Inaba, Y. Takeno, H. Aono,
T. Tsuboi, A. Tonouchi
67. Design, synthesis and evaluation of
Smac mimetics as selective cIAP-1 and
cIAP-2 inhibitors. H. Sun, J. Lu, L. Liu,
C. Yang, H. Yi, S. Wang
68. DNA methyltransferase inhibitors: Molecular
modeling and virtual screening.
J. L. Medina-Franco, N. Singh,
F. Lopez-Vallejo, D. Kuck, F. Lyko,
A. Dueñas-Gonzalez, G. Sbardella
69. Apoptosis triggers targeting selectively
resistant tumours. E. Genoux,
D. Lorendeau, H. Cortay, A. Di Pietro,
A. Boumendjel
70. 2-Aryl-benzimidazole-4-carboxamides
as novel SIRT1 activators. J. S. Disch,
C. B. Vu, L. McPherson, P. Ng,
J. E. Bemis, D. P. Carney, A. V. Lynch,
C. Loh, S. Ribich, P. Romero, J. J. Smith,
J. Song, D. J. Gagne, A. Cote, M. Davis,
E. Lainez, R. B. Perni
74–TECH
‡ Cooperative Cosponsorship
71. Synthesis and SAR of tricyclic isoquinoline
derivatives as HCV NS3 protease inhibitors.
J. Chen, L. Sun, F. Yu, G. Zhai,
D. Hernandez, A. K. Sheaffer, J. Friborg,
D. Barry, H. Mulherin, M. S. Lee,
F. McPhee, J. O. Knipe, K. Mosure,
N. A. Meanwell, P. M. Scola
72. In vitro and in vivo biological annotation
of a novel B-RAF inhibitor amenable for
clinical evaluation against B-RAF(V600E)harboring
human tumors. J. Lapierre,
C. Chen, Y. Liu, J. Szwaya, E. Chiesa,
C. Bull, E. Chang, C. Waghorne, J. Mao,
D. Lowe, K. Nguyen, E. Volckova,
Y. Wang, T. Hall, R. Savage, D. France,
M. A. Ashwell
73. Design and synthesis of simplified paclitaxel
analogs based on the T-taxol bioactive
conformation. J. Zhao,S.Bane,
K. Mukherjee, J. P. Snyder, H. Hu,
D. G. Kingston
74. Discovery of novel 2,4,6-trisubstituted
pyrimidine and pyridine based SIRT1 activators.
K. J. Koppetsch, C. J. Oalmann,
B. Szczepankiewicz, C. B. Vu,
G. Gualtieri, R. L. Casaubon, J. S. Disch,
A. V. Lynch, J. Song, D. J. Gagne,
A. Cote, M. Davis, E. Lainez, R. B. Perni
75. Discovery of a new class of selective
Chk1 “diazacarbazoles”. J. Drobnick,
B. Appleton, L. Axford, M. Beresini,
B. Burton, H. Chen, D. Clark, K. Clark,
P. Crackett, C. Ellwood, E. Gancia,
A. Ganguli, M. Gill, J. Goldstein,
S. Goodacre, J. Hewitt, D. Hurst, S. Kintz,
P. Lockey, J. Lyssikatos, S. Major,
C. McLeod, D. McNair, G. Medard,
R. Narukulla, R. Newman, S. Sideris,
C. Weismann, H. Hunt, K. Williams,
S. Malek, L. Gazzard
76. Phthalazinone pyrazoles as potent, selective
and orally bio-available inhibitors
of Aurora-A kinase. M. Prime,
F. Brookfield, S. Courtney, G. Georges,
B. Goller, A. Limberg, R. Marston,
P. Rueger, M. Rueth, W. von der Saal
77. Synthesis of novel osteogenic oxysterol
activators of the Hedgehog signaling
pathway. M. Epperson,W.Xiao,
F. Stappenbeck, F. Farouz
78. Putative exosite targeting for optimization
of 4EGI-1, a PPI inhibitor and a potent
anti-cancer agent. K. Takrouri,
Y. Wang, L. Chen, N. Zhang, B. H. Aktas,
G. Wagner, J. A. Halperin, M. Chorev
79. Structure-based computational design of
selective, small molecule PRMT5 inhibitors
for experimental therapeutics of cancer:
Protein modeling, virtual screening
and lead validation. K. V. Mahasenan,
F. Yan, R. Baiocchi, C. Li
80. In vitro and in vivo studies on the effectiveness
of free drug and nanoparticle encapsulated
silver carbene complexes on
H460 lung cancer. M. C. Deblock,
N. Robishaw, A. Knapp, M. J. Panzner,
A. Gupta, W. J. Youngs
81. Design, synthesis, and pharmacological
evaluation of multireceptor modulating
agents as potential atypical antipsychotics.
K. Peprah, S. V. Eyunni,
J. R. Etukala, V. Setola, B. L. Roth,
S. Y. Abblodeppey
82. Selective small molecules targeting
G-protein interactions to combat cancer
metastasis. M. J. Koyack,
R. V. Rajnarayanan
83. Synthetic strategies for developing multivalent
nitric oxide donors.
R. S. Nandurdikar,S.Y.Hong,
O. A. Oladeinde, A. E. Maciag,
J. E. Saavedra, L. K. Keefer
84. Synthesis of carbon-11-labeled casimiroin
analogs as new potential PET agents
for imaging of quinone reductase 2 and
aromatase expression in cancer.
M. Wang, M. Gao, G. D. Hutchins,
Q. Zheng
85. Property based optimization of lactam
based histone deacetylase (HDAC) inhibitors.
M. Cho, D. Song
86. Discovery of potent imidazo[1,2-a]pyrazine
Aurora kinase inhibitors.
D. B. Belanger, P. J. Curran, A. Hruza,
J. Voigt, Z. Meng, A. K. Mandal,
M. A. Siddiqui, A. D. Basso, K. Gray
87. Design, synthesis and biological evaluation
of pemetrexed(PMX) homologs for
folate receptor targeting multiple enzyme
antifolates. A. Gangjee, Y. Wang,
S. K. Desmoulin, C. Cherian,
L. H. Matherly, R. L. Kisliuk
88. Design, synthesis, and testing of orthoamido
diphenylamines as inhibitors of
MEK5. P. T. Flaherty, I. Chopra,
A. Diwan, D. A. Monlish, J. E. Cavanaugh
89. 2-Desamino and 2-methyl-6-substituted
pyrrolo[2,3-d]pyrimidine classical antifolates
as selective folate receptor substrates,
glycinamide ribonucleotide
formyltransferase inhibitors and antitumor
agents. A. Gangjee, S. Zhao, C. Cherian,
S. K. Desmoulin, L. H. Matherly,
R. L. Kisliuk
90. Synthesis and SAR of diaminopyrimidines
as c-Met inhibitors.
L. R. Weinberg, M. S. Albom,
T. S. Angeles, J. L. Diebold, J. Husten,
J. G. Lisko, K. L. Milkiewicz, S. Murthy,
G. R. Ott, B. A. Ruggeri, J. P. Theroff,
T. L. Underiner, B. D. Dorsey
91. Identification of potential proteins targets
of quercetin inhibition of HSP-70 induction
with a biotin-quercetin photoaffinity
agent. R. E. Wang, C. R. Hunt, J. Taylor
92. Development of polyamides as gene inhibitors
of heat shock protein 70 expression.
R. E. Wang, R. Pandita, C. R. Hunt,
J. Taylor
93. Rational design of disubstituted triazole
conjugated acridines with high selectivity
for the human parallel telomeric quadruplex.
S. Sparapani,S.M.Haider,
F. Doria, M. Gunaratnam, S. Neidle
94. Synthesis and characterization of rigidified
4EGI-1 mimetics that block proteinprotein
interaction, inhibit translation initiation,
and have anticancer activity.
R. Yefidoff-Freedman,Y.Wang,
L. Chen, N. Zhang, B. H. Aktas,
G. Wagner, J. A. Halperin, M. Chorev
95. Novel fluorescently labeled omega-3
fatty acid-taxiod conjugates.
W. T. Berger, E. Zuniga, J. D. Seitz,
L. V. Kuznetsova, I. Ojima
96. Discovery of TAK-700, a naphthylmethylimidazole
derivative, as a highly selective,
orally active 17, 20 lyase inhibitor for
prostate cancer. T. Kaku, T. Hitaka,
A. Ojida, N. Matsunaga, N. Terauchi,
F. Itoh, T. Tanaka, T. Hara, M. Yamaoka,
M. Kusaka, T. Okuda, S. Asahi, S. Furuya,
A. Tasaka
97. Structural requirements of histone
deacetylase (HDAC) inhibitors: Suberoyl
anilide hydroxamic acid (SAHA) analogs
modified at the C3 position. S. Choi,
S. V. Weerasinghe, M. H. Pflum
98. Antagonism of the Bak–Bcl-xL complex
by �-helix mimetics of varying curvatures.
S. Fletcher
99. Anticancer properties of gold(I)-N-heterocyclic
carbene complexes and their
silver(I) precursors. T. J. Siciliano,
M. C. Deblock, K. M. Hindi, S. Durmus,
M. J. Panzner, C. A. Tessier,
W. J. Youngs
100. Development of small molecule protein
lysine methyltransferase G9a inhibitors.
J. M. Yost, F. Liu, X. Chen,
A. Allali-Hassani, A. M. Quinn, T. J. Wigle,
D. Barsyte, G. A. Wasney, A. Dong,
I. Kozieradzki, G. Senisterra, I. Chau,
A. Siarheyeva, A. Van Deusen,
D. B. Kireev, A. Jadhav, J. M. Herold,
S. V. Frye, C. H. Arrowsmith,
W. P. Janzen, P. J. Brown, A. Simeonov,
M. Vedadi, J. Jin
101. From isothiazole to thiophene and thiazole:
A bioisosteric approach to the discovery
of potent imidazo[1,2-a]pyrazines
as Aurora kinase inhibitors. Z. Meng,
B. A. Kulkarni, A. D. Kerekes, J. Voigt,
A. K. Mandal, S. J. Esposite,
D. B. Belanger, P. P. Reddy, A. D. Basso,
K. Gray, S. Tevar, J. Jones, E. Smith,
M. A. Siddiqui, R. Doll
102. SAR of various Aurora selective chemotypes.
Z. Ji, Y. Dai, D. H. Albert,
J. J. Bouska, K. B. Glaser,
T. J. Magoc, k. D. Stewart, P. Tapang,
R. Wei, M. Michaelides
103. Development of oxazolidinone and oxazolobenzimidazole
positive allosteric
modulators for the treatment of Schizophrenia.
E. J. Brnardic, R. M. Garbaccio,
M. E. Fraley, M. E. Layton, G. D. Hartman,
M. A. Jacobson, B. C. Magliaro,
S. L. Huszar, P. H. Hutson, J. A. O’Brien,
J. M. Uslaner, K. L. Fillgrove, C. Tang,
Y. Kuo, S. M. Sur
104. 2-Substituted benzimidazoles as
metabotropic glutamate receptor-2 positive
allosteric modulators: A hit to lead
evaluation. C. Chen, U. Topiwala,
H. Jimenez, H. Chen, M. Uberti, K. Jones,
S. Topiol, M. Marzabadi, D. Doller
105. Structure activity relationship studies of
4-((((3S,6S)-6-benzhydryltetrahydro-2Hpyran-3-yl)amino)methyl)phenol
and its
analogs: Development of novel triple uptake
inhibitors as new generation antidepressants.
B. Gopishetty, S. Santra,
S. Ali, M. Reith, a. dutta
106. Probing S1� site of caspase-3: A new
hope for mechanism based treatment of
neurological disorders. A. K. Sharma
107. SAR evaluation of fused heterocyclic
quinolone carboxylic acid M1 positive allosteric
modulators. C. N. Di Marco,
V. Cofre, W. J. Ray, L. Ma, M. Wittmann,
M. A. Seager, K. A. Koeplinger,
C. D. Thompson, G. D. Hartman,
M. T. Bilodeau, S. D. Kuduk
108. New aryl sulfonamides compounds as
potent and selective 5-ht 6 receptor ligands.
A. Shinde, V. Reballi,
V. Tiriveedhi, P. Gudla, L. Kota,
A. Chindhe, N. Rambabu,
R. Kambhampati, R. Nirogi
109. Structure-activity relationships of 2,4diphenyl-1H-imidazole
analogs as CB2
receptor agonists for the treatment of
chronic pain. S. Yang, J. Smotryski,
J. Matasi, G. Ho, D. Tulshian,
W. J. Greenlee, R. Brusa, M. Beltramo,
K. Cox
110. High affinity ligands for opioid receptors
in the picomolar K i range: N-(2-[1,1�-biphenyl]-4-ylethyl)
analogs of 8-CAC.
J. M. Bidlack, D. J. Cohen,
J. M. Gargano, X. Jia, S. Jo,
M. A. VanAlstine, M. P. Wentland
111. Novel series of CB2 selective antagonists
for the treatment of autoimmune
disorders: Synthesis, functional evaluation
and ligand-steered modeling.
S. S. Phatak, R. R. Petrov,
F. Astruc-Diaz, C. N. Cavasotto,P.Diaz
112. 7-Hydroxy-benzopyran-4-one derivatives:
Discovery and structure-activity relationships
of PPAR � and -� (PPAR� and
�) dual agonists. N. Gavande, A. Matin,
M. S. Kim, N. K. Salam, J. R. Hanrahan,
R. H. Roubin, D. E. Hibbs
113. Synthesis and structure-activity relationships
of 3-aminopyridazine derivatives
of �-aminobutyric acid acting as
GABA C (�) antagonists. N. Gavande,
G. A. Johnston, J. R. Hanrahan,
M. Chebib
114. Design, synthesis and pharmacological
evaluation of fluorescent GABA C probes
for receptor visualization and localization
studies. N. Gavande, G. A. Johnston,
J. R. Hanrahan, M. Chebib
115. Design, synthesis, and pharmacological
evaluation of novel, selective �-aminobutyric
acid � (GABA C) receptor antagonists.
N. Gavande, K. Mewett,
G. A. Johnston, J. R. Hanrahan,
M. Chebib
116. Hepatitis C protease inhibitors based
on 2(1H)-pyrazinones. J. Gising,
A. Belfrage,P.Örtqvist, M. Larhed,
U. Danielson, A. Sandström
Photographing or recording
meeting sessions and/or
activities other than your own
are prohibited at all official
ACS events without written
consent from ACS.